JAB-24144

JAB-24144 is a small molecule drug candidate being developed by Jacobio Pharma, currently in the pre-clinical stage of development. It is part of the company's portfolio targeting tumor metabolic pathways, which are essential for the rapid proliferation and survival of cancer cells. By inhibiting specific metabolic enzymes or transporters, JAB-24144 aims to disrupt the energy production and biosynthetic requirements of tumors, thereby inhibiting growth. While specific details regarding its exact molecular target have not been widely publicized, it represents Jacobio's broader strategy of targeting metabolic vulnerabilities in oncology. As of 2022, it was listed among the company's internal research assets for potential application in solid tumors.